The fightn-CKD Study is testing an investigational drug to see whether it could help people with high blood pressure (hypertension) and chronic kidney disease (CKD). A high dose and a low dose of the investigational drug will be compared with a placebo. A placebo looks exactly like the investigational drug but contains no active medication.
Key eligibility criteria:
• Men and women ≥18 years of age.
• Systolic blood pressure ≥140 mmHg in seated position (or ≥130 mmHg if diabetic).
• Prior diagnosis of mild-to-severe CKD, defined as glomerular filtration rate (GFR) 25–75 mL/min/1.73 m2
. • Currently taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for >4 weeks.
• If taking an SGLT2 inhibitor for treating diabetes, the participant will have taken the drug for ≥8 weeks before screening and be expected to take the same dose for the study duration.
**There are other criteria that potential participants must meet in order to qualify for the study**
If you’re interested in participating in one of our Research Studies:
303-232-3366 ext 2170